These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

767 related items for PubMed ID: 24089054

  • 21. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
    Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS.
    J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
    [Abstract] [Full Text] [Related]

  • 22. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
    Akhondzadeh S, Safarcherati A, Amini H.
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
    [Abstract] [Full Text] [Related]

  • 23. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia.
    Grant PM, Huh GA, Perivoliotis D, Stolar NM, Beck AT.
    Arch Gen Psychiatry; 2012 Feb; 69(2):121-7. PubMed ID: 21969420
    [Abstract] [Full Text] [Related]

  • 24. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ, Riedel M, Müller N, Fischer W, Kohnen R.
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [Abstract] [Full Text] [Related]

  • 25. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM, Farokhnia M, Rezaei F, Gougol A, Yekehtaz H, Iranpour N, Salehi B, Tabrizi M, Tajdini M, Ghaleiha A, Akhondzadeh S.
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [Abstract] [Full Text] [Related]

  • 26. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
    Rezaei F, Mohammad-Karimi M, Seddighi S, Modabbernia A, Ashrafi M, Salehi B, Hammidi S, Motasami H, Hajiaghaee R, Tabrizi M, Akhondzadeh S.
    J Clin Psychopharmacol; 2013 Jun; 33(3):336-42. PubMed ID: 23609382
    [Abstract] [Full Text] [Related]

  • 27. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
    Kulkarni J, Gavrilidis E, Gwini SM, Worsley R, Grigg J, Warren A, Gurvich C, Gilbert H, Berk M, Davis SR.
    JAMA Psychiatry; 2016 Sep 01; 73(9):947-54. PubMed ID: 27438995
    [Abstract] [Full Text] [Related]

  • 28. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.
    Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE.
    Int J Neuropsychopharmacol; 2010 May 01; 13(4):451-60. PubMed ID: 19887019
    [Abstract] [Full Text] [Related]

  • 29. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
    Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, Wallace TL, Knoflach F, Dorflinger E, Wettstein JG, Bausch A, Garibaldi G, Santarelli L.
    JAMA Psychiatry; 2014 Jun 01; 71(6):637-46. PubMed ID: 24696094
    [Abstract] [Full Text] [Related]

  • 30. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
    Akhondzadeh S, Mohammadi N, Noroozian M, Karamghadiri N, Ghoreishi A, Jamshidi AH, Forghani S.
    Schizophr Res; 2009 Feb 01; 107(2-3):206-12. PubMed ID: 18789844
    [Abstract] [Full Text] [Related]

  • 31. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS, Gibel A, Ratner Y, Tsinovoy G, Strous RD.
    J Clin Psychopharmacol; 2006 Oct 01; 26(5):495-9. PubMed ID: 16974191
    [Abstract] [Full Text] [Related]

  • 32. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial.
    Cho SJ, Yook K, Kim B, Choi TK, Lee KS, Kim YW, Lee JE, Suh S, Yook KH, Lee SH.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan 15; 35(1):208-11. PubMed ID: 21095214
    [Abstract] [Full Text] [Related]

  • 33. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
    Keefe RS, Meltzer HA, Dgetluck N, Gawryl M, Koenig G, Moebius HJ, Lombardo I, Hilt DC.
    Neuropsychopharmacology; 2015 Dec 15; 40(13):3053-60. PubMed ID: 26089183
    [Abstract] [Full Text] [Related]

  • 34. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.
    Berk M, Gama CS, Sundram S, Hustig H, Koopowitz L, D'Souza R, Malloy H, Rowland C, Monkhouse A, Monkhouse A, Bole F, Sathiyamoorthy S, Piskulic D, Dodd S.
    Hum Psychopharmacol; 2009 Apr 15; 24(3):233-8. PubMed ID: 19330802
    [Abstract] [Full Text] [Related]

  • 35. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
    Lee BJ, Lee JG, Kim YH.
    J Psychopharmacol; 2007 Jun 15; 21(4):421-7. PubMed ID: 17092979
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Amiri A, Noorbala AA, Nejatisafa AA, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, Hajiazim M, Raznahan M, Akhondzadeh S.
    Hum Psychopharmacol; 2008 Mar 15; 23(2):79-86. PubMed ID: 17972359
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.